Читать книгу - "Живи долго! Научный подход к долгой молодости и здоровью - Майкл Грегер"

safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2019;39(2):e38–81. https://pubmed.ncbi.nlm.nih.gov/30580575/

3669

Redberg RF, Katz MH. Statins for primary prevention: the debate is intense, but the data are weak. JAMA. 2016;316(19):1979–81. https://pubmed.ncbi.nlm.nih.gov/27838702/

3670

Ornish D, Scherwitz LW, Billings JH, et al. Intensive lifestyle changes for reversal of coronary heart disease. JAMA. 1998;280(23):2001–7. https://pubmed.ncbi.nlm.nih.gov/9863851/

3671

Kelly J, Karlsen M, Steinke G. Type 2 diabetes remission and lifestyle medicine: a position statement from the American College of Lifestyle Medicine. Am J Lifestyle Med. 2020;14(4):406–19. https://pubmed.ncbi.nlm.nih.gov/33281521/

3672

Esselstyn CB Jr, Gendy G, Doyle J, Golubic M, Roizen MF. A way to reverse CAD? J Fam Pract. 2014;63(7):356–64b. https://pubmed.ncbi.nlm.nih.gov/25198208/

3673

Hochholzer W, Giugliano RP. Lipid lowering goals: back to nature? Ther Adv Cardiovasc Dis. 2010;4(3):185–91. https://pubmed.ncbi.nlm.nih.gov/20400493/

3674

Steinberg D, Witztum JL. Inhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levels. Proc Natl Acad Sci U S A. 2009;106(24):9546–7. https://pubmed.ncbi.nlm.nih.gov/19506257/

3675

Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005;37(2):161–5. https://pubmed.ncbi.nlm.nih.gov/15654334/

3676

Jaworski K, Jankowski P, Kosior DA. PCSK9 inhibitors – from discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade. Arch Med Sci. 2017;13(4):914–29. https://pubmed.ncbi.nlm.nih.gov/28721159/

3677

Qamar A, Bhatt DL. Effect of low cholesterol on steroid hormones and vitamin E levels: just a theory or real concern? Circ Res. 2015;117(8):662–4. https://pubmed.ncbi.nlm.nih.gov/26405182/

3678

Blom DJ, Djedjos CS, Monsalvo ML, et al. Effects of evolocumab on vitamin E and steroid hormone levels: results from the 52-week, phase 3, double-blind, randomized, placebo-controlled DESCARTES study. Circ Res. 2015;117(8):731–41. https://pubmed.ncbi.nlm.nih.gov/26228031/

3679

Qamar A, Libby P. Low-density lipoprotein cholesterol after an acute coronary syndrome: how low to go? Curr Cardiol Rep. 2019;21(8):77. https://pubmed.ncbi.nlm.nih.gov/31250329/

3680

Hochholzer W, Giugliano RP. Lipid lowering goals: back to nature? Ther Adv Cardiovasc Dis. 2010;4(3):185–91. https://pubmed.ncbi.nlm.nih.gov/20400493/

3681

Glueck CJ, Gartside P, Fallat RW, Sielski J, Steiner PM. Longevity syndromes: familial hypobeta and familial hyperalpha lipoproteinemia. J Lab Clin Med. 1976;88(6):941–57. https://pubmed.ncbi.nlm.nih.gov/186545/

3682

Packard CJ. LDL cholesterol: How low to go? Trends Cardiovasc Med. 2018;28(5):348–54. https://pubmed.ncbi.nlm.nih.gov/29336946/

3683

Gotto AM. Low-density lipoprotein cholesterol and cardiovascular risk reduction: how low is low enough without causing harm? JAMA Cardiol. 2018;3(9):802–3. https://pubmed.ncbi.nlm.nih.gov/30073330/

3684

Packard CJ. LDL cholesterol: How low to go? Trends Cardiovasc Med. 2018;28(5):348–54. https://pubmed.ncbi.nlm.nih.gov/29336946/

3685

Steinberg D. The cholesterol controversy is over. Why did it take so long? Circulation. 1989;80(4):1070–8. https://pubmed.ncbi.nlm.nih.gov/2676235/

3686

Morgan DJ, Dhruva SS, Coon ER, Wright SM, Korenstein D. 2018 update on medical overuse. JAMA Intern Med. 2019;179(2):240–6. https://pubmed.ncbi.nlm.nih.gov/30508032/

3687

Lyu H, Xu T, Brotman D, et al. Overtreatment in the United States. PLoS One. 2017;12(9):e0181970. https://pubmed.ncbi.nlm.nih.gov/28877170/

3688

Rothberg MB, Scherer L, Kashef MA, et al. The effect of information presentation on beliefs about the benefits of elective percutaneous coronary intervention. JAMA Intern Med. 2014;174(10):1623–9. https://pubmed.ncbi.nlm.nih.gov/25156687/

3689

Rothberg MB, Sivalingam SK, Ashraf J, et al. Summaries for patients: patients’ and cardiologists’ beliefs about a common heart procedure. Ann Intern Med. 2010;153(5):I46. https://pubmed.ncbi.nlm.nih.gov/20820040/

3690

Laukkanen JA, Kunutsor SK, Lavie CJ. Percutaneous coronary intervention versus medical therapy in the treatment of stable coronary artery disease: an updated meta-analysis of contemporary randomized controlled trials. J Invasive Cardiol. 2021;33(8):E647–57. https://pubmed.ncbi.nlm.nih.gov/34338654/

3691

Harvard Heart Letter. COURAGE to make choices. Harvard Health Publishing. https://www.health.harvard.edu/newsletter_article/courage-to-make-choices. Published June 1, 2007. Accessed April 5, 2022.; https://www.health.harvard.edu/newsletter_article/courage-to-make-choices

3692

Al-Lamee R, Thompson D, Dehbi HM, et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet. 2018;391(10115):31–40. https://pubmed.ncbi.nlm.nih.gov/29103656/

3693

Kolata G. ‘Unbelievable’: heart stents fail to ease chest pain. The New York Times. https://www.nytimes.com/2017/11/02/health/heart-disease-stents.html. Published November 2, 2017. Accessed April 5, 2022.; https://www.nytimes.com/2017/11/02/health/heart-disease-stents.html

3694

Al-Lamee R, Thompson D, Dehbi HM, et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet. 2018;391(10115):31–40. https://pubmed.ncbi.nlm.nih.gov/29103656/

3695

Doenst T, Haverich A, Serruys P, et al. PCI and CABG for treating stable coronary artery disease: JACC review topic of the week. J Am Coll Cardiol. 2019;73(8):964–76. https://pubmed.ncbi.nlm.nih.gov/30819365/

3696

Rothberg MB. Coronary artery disease as clogged pipes: a misconceptual model. Circ Cardiovasc Qual Outcomes. 2013;6(1):129–32. https://pubmed.ncbi.nlm.nih.gov/23322809/

3697

Trumbo PR, Shimakawa T. Tolerable upper intake levels for trans fat, saturated fat, and cholesterol. Nutr Rev. 2011;69(5):270–8. https://pubmed.ncbi.nlm.nih.gov/21521229/

3698

World Health Organization. Countdown to 2023: WHO report on global trans-fat elimination 2021. Geneva: 2021.; https://www.who.int/publications/i/item/9789240031876

3699

Wanders AJ, Zock PL, Brouwer IA. Trans fat intake and its dietary sources in general populations worldwide: a systematic review. Nutrients. 2017;9(8):E840. https://pubmed.ncbi.nlm.nih.gov/28783062/

3700

Kahle L, Krebs-Smith SM, Reedy J, Rodgers AB, Signes C. Identification of top food sources of various food components. Epidemiology and Genomics Research Program. https://epi.grants.cancer.gov/diet/foodsources/top-food-sources-report-02212020.pdf. Updated November 30, 2019. Accessed April 5, 2022.; https://epi.grants.cancer.gov/diet/foodsources/top-food-sources-report-02212020.pdf

3701

Xu Z, McClure ST, Appel LJ. Dietary cholesterol intake and sources among U.S. adults: results from National Health and Nutrition Examination Surveys (NHANES), 2001–2014. Nutrients. 2018;10(6):E771. https://pubmed.ncbi.nlm.nih.gov/29903993/